On February 28, MetaStat, Inc. (OTCQB: MTST), a precision medicine company developing novel anti-metastatic treatment solutions for patients with aggressive cancer, reported that positive results and the successful completion of the pilot research project with Celgene Corporation (Press release, MetaStat, FEB 28, 2018, https://ir.stockpr.com/metastat/company-news/detail/398/metastat-announces-positive-topline-data-showing-over-50-reduction-in-cancer-metastasis-from-preclinical-studies-evaluating-inhibition-of-the-mapkapk2-kinase-pathway [SID1234524308]). In preclinical models of aggressive breast cancer, data showed cancer cell invasion and metastasis was reversed through inhibition of a specific serine-threonine kinase responsible for activation of the MenaINV protein. Over-expression of the MenaINV protein isoform has been shown to play an important role in driving progression and metastatic dissemination in aggressive types of solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to have successfully completed our research project that demonstrated a 50% or more reduction in distant metastasis in animal models of aggressive breast cancer," stated Douglas A. Hamilton, MetaStat’s President, CEO and Director. "These results confirm our pathway forward for development of MAPKAPK2 inhibitors selected for specificity against the Mena protein." MetaStat has received the final milestone payment of approximately $100,000 and completed its obligations under the pilot research agreement. MetaStat has received aggregate milestone payments of approximately $1 million from Celgene pursuant to the terms of the agreement.
Detailed results from these in vitro and in vivo studies will be submitted to a future medical conference and for publication.